Although it is known that the majority of patients with type-1 deletions have severe cognitive deficits and developmental delay than patients with intragenic NF1 mutations, the variability of the clinical phenotype among type-I NF1 microdeletion patients could be addressed by considering the role played by pseudo-dominance and variants in the modifier genes. The gene discussed is NF1; the disease is Global developmental delay.